MedTrace Logo

Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients

NCT01298102 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2011-02-17

No results posted yet for this study

Summary

In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There is no data concerning the immunogenicity nor the security of the adjuvanted-A/H1N1 vaccine in renal disease patients. The aim of this study is to observe the effects of this vaccine on transplanted and hemodialyzed patients.

Conditions

  • Decreased Immunologic Activity [PE]
  • Influenza
  • Rejection

Interventions

BIOLOGICAL

Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)

intramuscular injection of 1 dose vaccine

Sponsors & Collaborators

  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Daniel Abramowicz, PhD · Hospital Erasme

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01298102 on ClinicalTrials.gov